Maze Therapeutics, Inc./$MAZE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Maze Therapeutics, Inc.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
- Ticker
- $MAZE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 141
- Headquarters
- South San Francisco, United States
- Website
- www.mazetx.com
MAZE Metrics
BasicAdvanced
$1.6B
-
-$2.52
-
-
Price and volume
Market cap
$1.6B
52-week high
$53.65
52-week low
$21.95
Average daily volume
894K
Financial strength
Current ratio
18.31
Quick ratio
18.026
Long term debt to equity
0.123
Total debt to equity
0.133
Interest coverage (TTM)
-81.03%
Profitability
EBITDA (TTM)
-143.707
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-667.95%
Operating margin (TTM)
-728.06%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
-21.79%
Return on equity (TTM)
-37.35%
Valuation
Price to revenue (TTM)
78.822
Price to book
3.64
Price to tangible book (TTM)
3.64
Price to free cash flow (TTM)
-14.755
Free cash flow yield (TTM)
-6.78%
Free cash flow per share (TTM)
-2.013
Growth
Revenue change (TTM)
700.00%
Earnings per share change (TTM)
-49.67%
What the Analysts think about MAZE
Analyst ratings (Buy, Hold, Sell) for Maze Therapeutics, Inc. stock.
Analyst projections of the future price of Maze Therapeutics, Inc. stock.
Bulls say / Bears say
In the 12 evaluable HORIZON patients, MZE829 cut average urinary albumin by 35.6% at week 12, and half had reductions above 30%; no serious treatment-related adverse events were reported. This is an encouraging early signal in APOL1-mediated kidney disease, though it still needs confirmation in larger trials. (SEC)
MZE782 has shown strong target engagement in Phase I, including a reported 42-fold increase in urinary phenylalanine excretion at the top dose. Its Phase II PKU trial is now under way, giving Maze another clinical programme beyond its lead kidney drug. (Investing.com, SEC)
Maze reported $494.9 million in cash and investments at the end of June 2026 and expects its funds to last into 2029. That gives it time to pursue upcoming clinical milestones without an immediate need to raise more capital. (SEC)
The MZE829 efficacy readout covers just 12 patients and reports a short-term change in proteinuria, not proof that the drug slows kidney decline or prevents dialysis. Larger Phase II cohorts and pivotal testing will need to confirm whether the signal holds. (SEC)
Maze is developing MZE829 against Vertex’s competing APOL1 programme, which is further along clinically. The company says it is using Vertex’s trial results to help shape its own pivotal-study design, underlining the competitive and timing risk. (Investing.com)
Maze remains pre-revenue and reported a $44.7 million Q2 2026 net loss, up from $33.7 million a year earlier, while research and development spending increased. It has also recently raised equity, so continued development could bring further cash burn and dilution despite its current runway. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
MAZE Financial Performance
Revenues and expenses
MAZE Earnings Performance
Company profitability
Upcoming events
No upcoming events
MAZE News
AllArticlesVideos
Funds containing MAZE
Fund name | Fund size | $MAZE weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.10% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.